The Role of Immune Response and the Impact of Biological Drugs in Psoriasis Patients

Amedeo Amedei and Mario Milco D’Elios
University of Florence
Italy

1. Introduction
Psoriasis is a chronic immune-mediated skin disease with a intricate pathogenesis and a strong genetic background (Nickoloff et al., 2007a), that affects approximately 1–3% of the worldwide population, with an equal sex distribution (Stern et al., 2004). The main type of psoriasis is chronic plaque psoriasis (Cp) accounting for approximately 85–90% of all cases. The Cp is characterized by erythematous scaly plaques, usually on elbows, knees, scalp and buttocks. Plaque size can diverge from minimal to the involvement of the entire skin surface (erythrodermic psoriasis) (C. E. Griffiths et al., 2007; Nestle et al., 2009). Other forms of psoriasis comprise guttate psoriasis, inverse, palmoplantar and generalized pustular psoriasis (C. E. Griffiths & Barker, 2007; Nestle et al., 2009).

The concept of psoriasis as “the disease of healthy people” has long been surpassed, nowadays we know that during the time course of this disease, as a consequence of dysregulated immunity and ensuing inflammation, certain conditions may appear at somewhat unpredictable time points in a progressive fashion; these so-called co-morbidities, although targeting different organs, share common pathogenetic factors. They often become manifest years after the onset of skin manifestations and are often observed in severe forms of psoriasis.

Psoriatic Arthritis (PsA) is traditionally included among common co-morbidities, even if it should be rather considered a component of the clinical spectrum of psoriatic disease. PsA involves peripheral joints, the axial skeleton, sacroiliac joints, nails and enthuses, and is frequently associated with psoriatic skin lesions. The prevalence of PsA ranges from 5 to 40% among psoriatic patients lesions (D. D. Gladman, 2009; Nograles et al., 2009).

Recently, co-morbidities like cardiovascular disease, obesity and metabolic syndrome have been found to be associated with psoriasis, raising the idea that psoriasis might not be only a skin disorder (Gerdes & Mrowietz, 2009; Kimball et al., 2008a; Menter et al., 2008).

Psoriasis patients suffer also from considerable psychological and financial burdens resulting in a significantly impaired quality of life (Rapp, et al., 1999); likewise traditional systemic psoriasis therapies (methotrexate [MTX], cyclosporin A, retinoids or PUVA therapy) have a potential for long-term toxicity and cannot always provide plenty disease improvement (Pathirana et al., 2009; Smith et al., 2009). Thus, the development of agents efficiently targeting key steps in the pathogenesis of psoriasis and co-morbidities is clearly an important goal.
2. Pathogenesis

Psoriasis is thought to be a complex condition resultant by a combination of genetic and environmental factors. The acute forms of psoriasis, guttate and generalized pustular psoriasis (von Zumbusch psoriasis), are both associated with infections (typically b-haemolytic streptococcal or a viral infection). Other triggering factors which may elicit psoriasis in predisposed individuals include trauma (Koebner phenomenon) (Eyre & G. G. Krueger, 1984), HIV infection (Reveille et al., 1990), psychogenic stress (Gupta et al., 1989) and definite drugs (e.g. lithium, beta-blockers, interferons and high dose corticosteroids) (Abel et al., 1986).

Histological examination of psoriatic plaques reveals hyperproliferation of keratinocytes (Kcs) with parakeratosis, increased angiogenesis and dermal infiltration of immune cells, predominantly T cells, neutrophils, macrophages and dendritic cells (DCs) (Figure 1) (Nestle et al., 2009; Nickoloff et al. 2007b).

Fig. 1. Psoriatic skin lesions evolution. Different stimuli (e.g. infections, etc.) can trigger an initial episode of psoriasis in genetically predisposed individuals. After starting, the earliest events driving the inflammatory eruption are the secretion of INF-α from pDCs (plasmacytoid dendritic cells) and the production of TNF-α by immune cells of both innate and adaptive response. Large amounts of IFN-α induce activation of the local immune effector cells that secrete pro-inflammatory cytokines. TNF-α is a very active cytokine of the inflammatory infiltrate and is principally secreted by activated macrophages (MΦ), dermal DCs, keratinocytes and T cells. The elevated levels of TNF-α lead to the maturation of DCs into forceful APCs (antigen presenting cells) and, with other cytokines, up-regulates the expression of endothelial E-selectin and ICAM-1 attracting further CLA+ T cells in the skin. Also, the panel of cytokines released by T cells contributes to the stimulation of epidermal keratinocytes and is at least, in some measure, responsible for typical psoriasis skin changes. They induce the expression of ICAM-1, CD40 and MHC-II and trigger keratinocyte hyper-proliferation.
The increased dermis vascularity is driven by angiogenic factors, such as VEGF (vascular endothelial growth factor), highly present in psoriasis plaques (Detmar et al., 1994). Also, the interaction between VEGF and the angiopeptin/Tie signaling pathway is modulated by TNF-a (Tumour necrosis factor-a), that together with interleukin 12 (IL-12) and IL-23 are well known to be crucial immunological mediators in psoriasis. (Holash et al., 1999; Kuroda et al., 2001). Whereas IL-12 induces Th1 (T helper 1) differentiation and thus increases the production of TNF-a, IL-23 stimulates primarily Th17 cells, which secrete most importantly pro-inflammatory cytokines such as IL-17 and IL-22 (Nestle et al., 2009; Toichi et al., 2006; Torti & Feldman, 2007).

Increased concentrations of TNF-a and IL-12/IL-23 have been found as in psoriatic skin (Nestle et al., 2009) as in the synovial fluid and tissue of patients with PsA (FitzGerald & Winchester, 2009; Ritchlin et al, 1998). Their role in psoriasis genesis is highlighted by the successful treatment of psoriasis by agents blocking these cytokines (Boker et al., 2007; Mössner et al., 2008; Scalon et al., 2009). In addition, polymorphisms of IL-23 receptor gene and gene encoding the shared p40 subunit of IL-12 and IL-23 have been linked to psoriasis development (Elder et al., 2010; Hüffmaier et al., 2009; Nestle et al., 2009).

### 3. Genetics of psoriasis

Family studies have shown that psoriasis has a strong genetic component although the inheritance pattern is still unclear. 71% of patients with childhood psoriasis have a positive family history (Morris et al., 2001) and analysis of concordance rates in twin studies show a threelfold increased risk of psoriasis in monozygotic twins compared to dizygotic twins (Brandrup et al., 1978; Pisani & Ruocco, 1984).

At least ten chromosomal loci have been identified showing statistically significant evidence for linkage to psoriasis (PSORS 1-10). However, the only region that has consistently been identified in genetic screens of families with psoriasis is the major-histocompatibility complex (MHC) region on chromosome 6 named PSORS1 (Capon et al., 2008; Nair et al., 2006), that is responsible for up to 50% of genetic susceptibility to psoriasis. Within PSORS1 the human leukocyte antigen-C (HLA-C) gene which is the strongest candidate gene for psoriasis, precisely its allele HLACw6 (HLA-Cw*0602) the predominant risk allele (Nair et al., 2006): individuals with this allele have a 10-20-fold increased risk of developing psoriasis (Mallon et al., 1999).

HLA-Cw6 positive and negative psoriasis patients may exhibit distinctive clinical phenotypes (Henseler & Christophers, 1985): guttate psoriasis is mostly confined to HLA-Cw6+ patients meanwhile psoriatic nail disease, palmoplantar pustulosis and psoriatic arthritis are more common in HLA-Cw6- patients (Fan et al., 2007; Gudjonsson et al., 2006). Furthermore, partial or total remission during pregnancy is much more frequent in HLA-Cw*0602+ women (Gudjonsson et al., 2006).

Despite this strong association, the functional role of HLA-Cw6 remains unknown; as far as we know HLA-Cw6 may exert its effect through the specific or the innate immune system (Figure 2): HLA-Cw6 may act via the adaptive immune system by its antigen presenting capacity and the fact that guttate psoriasis (sturdily associated with HLA-Cw6) is triggered by streptococcal pharyngitis (J. C. Prinz, 2001), supports this hypothesis. HLA-Cw6 may also exert an innate immune response via its interaction with KIRs (killer immunoglobulin-
like receptors) of natural killer (NK) and natural killer T (NKT) cells, which are implicated, in psoriasis pathogenesis (Nickoloff, 1999a). KIRs recognize different types of HLA-C molecules leading to either an overall activating or inhibitory immune response. KIRs have been associated with psoriasis and PsA (Martin et al., 2002). HLA-Cw6 is a natural ligand for KIR2DL1 (an inhibitory receptor) and it is possible that interaction between HLA-Cw6 and PaKIR2DL1 would lead to aberrant function of lymphoid cells in psoriasis pathogenesis.

**Fig. 2. Hypothetical regulating role of HLA-Cw6 in both specific and innate immune responses.**

HLA-Cw6 expressed on APCs can trigger specific immune responses by presentation of processed antigen to the TCR of CD8+ T cells. Also, innate immune response can be elicited by interaction of HLA-Cw6 with its natural Killer immunoglobulin-like receptors expressed on NK and NKT cells.

A new psoriasis susceptibility gene ZNF313/RNF114, which may regulate T cell activation through ubiquitin ligase activity, has been identified (Capon et al., 2008). All these data further supports the concept that multiple gene products share a role in the immune regulation of psoriasis, contributing to disease pathogenesis.

**4. Immune response**

Although the initial event triggering a psoriatic lesion is still unknown many factors have been shown to play a role in the pathogenesis of psoriasis: physical trauma, infections, stress, drugs, alcohol and smoking can all trigger an initial episode of psoriasis in individuals with genetic predisposition (Bowcock & J. G. Krueger, 2005).

This initial trigger activates dendritic cells, favoring their migration to skin-draining lymph nodes, where antigen-specific T cells (primed by DCs) differentiate into effector T cells,
which then traffic to the skin where they induce – in concert with other cells, especially dermal DCs – the creation of a primary psoriatic plaque. During this step some T cells and DCs start to infiltrate the epidermis, where stimulating KCs support the typical epidermal changes (Bowcock & J. G. Krueger, 2005).

Epidermal keratinocytes are able to recruit and activate T cells and most T cells infiltrating psoriatic skin are divided into Th1 (CD4+) and T cytotoxic 1 (Tc1; CD8+) subsets (J. G. Krueger, 2002). Two further T cell subtypes, Th17 cells (McKenzie et al., 2006) and regulatory T cells (Treg) (Sugiyama et al., 2005) have been identified as important contributors to the pathogenesis of autoimmune diseases such as psoriasis (Figure 3).

Fig. 3. Role of CD4 T cell subtypes in psoriasis.

www.intechopen.com
Th1 and Th17 pro-inflammatory cytokines mediate keratinocyte hyperproliferation and trigger a ‘vicious cycle’ of inflammation. IL-23 secreted principally by keratinocytes, dendritic cells and macrophages is critical for maintenance of Th17 function. Low levels of anti-inflammatory cytokines released by Th2 and Tregs potentially counteract but cannot balance the effects of Th1/Th17 cytokines.

From the foregoing it is clear that the contribution of both innate and adaptive immune responses are important in mediating the inflammatory psoriasis cascade (Gaspari, 2006) (Figure 1).

### 4.1 Aberrant activation of the innate fraction of the skin immune system

The present knowledge of the possible role of innate immunity cells (Kcs, Dcs, neutrophils, macrophages, NK and NKT cells) in psoriasis will be discussed.

#### 4.1.1 Keratinocytes in psoriasis

Over the last 20 years it has been regularly discussed if psoriatic skin lesions arise from a primary alteration in epidermal keratinocytes or in T cells (Figure 1); the current view is that infiltrating T cells initiate and maintain psoriasis. In this vision, cytokines (e.g., IL-1, IL-6 and IFN-γ) secreted by T cells and other inflammatory cells (DCs, macrophages and neutrophils) would trigger KCs hyperproliferation, inducing epidermal hyperplasia (J. G. Krueger, 2002). In particular, IL-23, whose expression is increased in psoriatic lesion (Piskin et al., 2006), has been implied in the development of epidermal acanthosis, most likely through the induction of IL-22 (Zheng et al., 2007); injection of IL-23 into mouse dermis induces as dermal inflammation as epidermal hyperplasia similarly to features seen in psoriasis (J. R. Chan et al., 2006).

Previous studies (J. G. Krueger, 2002) suggested an additional explanation for the chronic epidermal hyperplasia in psoriatic lesions: the migration of T cells in the epidermis would firstly break the basement membrane, which has been shown to have large areas with reduced staining intensity for collagen IV and laminins (Fleischmajer et al., 2000), and secondly disrupt desmosome connection between KCs. These two events could be interpreted by KCs as an injury and therefore induce a wound repair response. As a consequence many mitogenic cytokines would be released by KCs triggering a regenerative epidermal growth. Hence, T cells in psoriatic epidermis would be responsible for the chronic hyperplasia as by releasing pro-inflammatory cytokines as by disrupting epidermal integrity.

Another evidence against the fundamental role of T cells in psoriasis arise from the observation that HIV+ patients (which usually have reduced number of CD4+ T cells) develop psoriasis with similar frequency as the rest of the population (Namazi, 2004).

Finally, in 2005 Zenz et al. reported an interesting animal model with psoriasis-like features (Zenz et al., 2005); They knocked out JunB and c-Jun, two components of the AP-1 transcription factor, which control cell proliferation and differentiation, cytokine production, and stress responses in the skin. The importance of this animal model lies in the fact that JunB is located in the PSORS6 locus, which has been shown to be a psoriasis susceptibility region (Hensen et al., 2003). Interestingly, these mice developed not only...
inflammatory skin lesions but also a form of destructive arthritis. This evidence suggested that alteration in the epidermal Jun-pathway may be sufficient to induce inflammatory reactions in the skin as well as in the joints. At the skin level these mice showed typical hallmarks of psoriasis: hyperkeratosis, enlarged blood vessels, infiltration of T cells and neutrophils, and up-regulation of pro-inflammatory cytokines.

The most intriguing aspect was the examination of the T cells role in development of psoriasis in a genetic model: upon deletion of JunB and c-Jun proteins in Rag2-deficient mice (mice deficient of T/B cells), skin changes like in psoriasis were still induced, though they were milder. These data suggest a minor role for T cells in the etiology of psoriasis-form skin inflammation, and that primary alterations in KCs were sufficient to drive psoriasis-form changes in the mice skin. But before stating that KCs instigate psoriasis in humans, the relevance of this model must be discussed further. A recent study (Haider et al., 2006) showed that the JunB was expression increased in psoriatic plaques instead of decreased/deleted as in the Zenz mouse model, suggesting a role for JunB as a transcriptional activator of disease-related genes in psoriatic KCs.

The ongoing discussion about the primary instigator of psoriasis reflects the complexity of this disease and the still elusive interplay between KCs and immune cells in driving psoriasis.

This problem was further addressed in another mouse model, in which STAT-3 was constitutively activated in basal KCs under the control of the keratin 5 promoter (K5.Stat3C) (Sano et al., 2005). As in human psoriatic plaques, induced lesions of K5.Stat3C mice shown a considerable number of CD4+ T and CD8+ T cells in the epidermis. For psoriasis development, this model required both activated STAT-3 in KCs and activated T cells in the dermis and epidermis of the transgenic rodents, suggesting the theory that KCs and T cells could act together in psoriasis pathogenesis.

4.1.2 Neutrophilic granulocytes

Early studies in psoriasis (Jablonska, 1986), in which the initial (pre-pinpoint) lesions were studied histologically, indicated that the primary abnormality in a developing lesion of psoriasis is the perivascular accumulation of neutrophils as well as their epidermis invasion (Kogoj phenomenon). Next, these neutrophils accumulations lead to microscopically detectable microabscesses (Munro abscesses). In many patients with psoriasis, these micropustules may enlarge and become clinically visible as sterile 2–3-mm pustules. In some patients, pustules are the primary visible abnormality, often on an erythematous base.

The presence of neutrophils must be important for the formation of psoriatic skin lesions, in fact agranulocytosis has been reported to result in the remission of psoriasis (Toichi et al., 2000). Next, neutrophils can contribute to the hyperproliferation of keratinocytes by the effects of human leucocyte-derived elastase (Rogalski et al., 2002).

4.1.3 Natural killer T cells

The potential role of cells expressing NK receptors in psoriatic skin was firstly proposed by Nickoloff (Nickoloff et al., 1999b); in further experiments, he showed that a CD94+/CD161+ NKT cell line (isolated from a psoriatic patient) injected in prep[psoriatic skin of a SCID
Psoriasis

mouse, gave rise to creation of psoriatic plaque characterized by diffuse keratinocyte expression of CD1d, CD161+ T cells infiltration and marked presence of mRNA for IFN-c and IL-15 (Nickoloff et al., 2000).

In line with these data, it seems that constitutive CD1d expression on prepsoriatic skin keratinocytes represents a primary prerequisite that ensures their contact with the CD161 molecule on NKT cells. This interaction might also represent one of the critical events in the triggering of psoriasis as CD1d-bearing keratinocytes can present endogenous (self) or exogenous (bacterial, viral) glycolipids to NKT-cells. Consequently to the recognition of glycolipid antigens, NKT cells produce large amounts of IFN-c which induces stronger keratinocyte expression of CD1d; in this way the pathogenic mechanism of psoriatic plaques is not only initiated but also maintained.

Numerous studies have addressed the issue of NKT cells in the lesional skin of psoriasis patients and a constant result evidenced by independent groups of investigators is that CD161+ T cells appear in greater numbers in lesional skin of patients with psoriasis than in normal healthy skin and/or prepsoriatic skin (Bonish et al., 2000; Cameron et al., 2002; Curry et al., 2003; Vissers et al., 2004a).

However, Curry group shown a greater frequency of CD161+ T cells yet in the prepsoriatic skin in comparison with the normal skin, suggesting that certain immune response dysregulations exists in the uninvolved skin and creates a milieu, promoting the psoriatic lesions onset (Curry et al., 2003).

A flow cytometric analysis of psoriatic tissue-infiltrating T cell demonstrated the presence of CD3+ cells expressing also CD16, CD56, CD158b, CD94 or NKG2A and CD4–CD8–, the majority of these is a subset of NKT cells (Liao et al., 2006). In addiction a recent study (Zhao et al., 2008) confirmed that NKT cells as well as CD1d molecules were increased within psoriatic skin.

The supposed pathogenic role of NKT cells in psoriasis is also supported by the effects of different pharmacological treatments, that decreases NKT cell numbers in psoriatic plaques, in particular the clinical efficacy of betamethasone dipropionate (Bovenschen et al., 2007; Vissers et al., 2004b, 2008;) and similarly of alefacept that induce an improvement in plaque severity accompanied by significant reductions of dermal CD94+ and CD161+ (Bovenschen et al., 2007).

In general, these data strongly indicate that lesional CD94+ and CD161+ NKT cells actively participate in the development and/or maintenance of psoriatic lesions, but the relative relevance of each of these subsets remains elusive. However, it might be hypothesized that epidermal NKT cells play a major pathogenic role due to their direct interaction with CD1d+ keratinocytes and the resulting hyperproliferation while the dermal component of NKT cells participates in the immune response through the interaction with CD1d-bearing dermal dendritic cells and monocytes.

Likewise other Th1-mediated autoimmune diseases, psoriasis is associated with decreased numbers of circulating NKT cells (Cameron et al., 2003; Koreck et al., 2002; van der Vliet et al., 2001;); Koreck reported that decreased percentage of NKT cells population in blood of psoriasis patients tended to be even lower in those with frequently relapsing (Koreck et al., 2002). Moreover, different systemic therapy regimens resulted in the recovery of these cells,
but their percentage remained significantly lower in comparison with healthy control subjects. In contrast, Langewouters group showed that the number of circulating CD94+ and CD161+ cells was significantly higher in patients with moderate-to-severe as compared to patients with mild psoriasis (Langewouters et al., 2008). It has been also reported that circulating CD161+ NKT cells in people with severe psoriasis belong to Th1 cells (W. L. Chan et al., 2003) and that treatment with alefacept or efalizumab causes significant reduction in their number (Larsen et al., 2007; van Lingen et al., 2008). These observations imply that distinct subsets of NKT cells differentially regulate immune responses and that their relative imbalance might be of importance in the psoriasis pathogenesis, but the precise impact of these findings remains unclear.

4.1.4 Accessory cells (Dendritic cells and macrophages)

DCs are involved in the development of tolerance (Steinman et al., 2003) and are the unique professional antigen-presenting able to take up antigen in the tissue they reside in and to migrate to the draining lymph nodes; here activate naive T cells, generating specific T-cell responses (Teunissen, 2005).

In the peripheral tissues DCs receive all kinds of microenvironment signals, that influence the their maturation process, determining the phenotype and function of mature DCs and their type 1/type 2 polarizing potential. In case of risk (e.g. infection, cancer), DCs will transform into strong stimulatory antigen presenting cells, whereas under non pathological steady-state conditions DCs do not reach full maturation and they will present self-peptides/MHC complexes in the presence of insufficient costimulatory molecules, inducing T-cell anergy or expansion of regulatory T cells (peripheral tolerance). If this delicate balance of immune reactivity vs. tolerance is broken, chronic inflammatory diseases, like psoriasis, may develop.

In the absence of pathogenic substances, stress signals from neighbouring cells (e.g. necrotic cells) can activate DCs enabling them to stimulate naive T cells (Gallucci et al., 1999). In relation to this, Krueger has expressed an remarkable view concerning traumatic injuries (breaches in the basement membrane and disruption of desmosome connections between adjacent keratinocytes) caused by migrating T cells and DCs in the epidermis, that are possibly involved in the development of psoriasis lesions (J. G. Krueger, 2002). Keratinocytes will respond to these defects by overproduction of cytokines, among others TNF-α, a key cytokine to induce DC migration/maturation.

Another exciting point to mention is the observation that DC development is also affected by mutual interaction with NKT cells (Taniguchi et al., 2003): weak responses by NKT cells to glycolipid/CD1d complexes can be enhanced by DC-derived IL-12, resulting in up-expression of IFN-γ by NKT cells. This interaction may be relevant in psoriasis.

DCs are numerous in the dermal part of psoriasis skin and many of them exhibit an activated phenotype (CD80+, CD83+, CD86+ and DC-LAMP+) (Abrams et al., 2000; Teunissen, 2005) and may be an important source of TNF-α (Nickoloff et al., 1991; Zhou et al., 2003).

Recent evidences from different genetic mouse models show that also the macrophages can contribute to T-cell-mediated and epidermis-mediated psoriasis-form skin inflammation.
and in particular the data from the CD18hypo PL/J psoriasis mouse model demonstrate (Wang et al., 2009) that the psoriasis-form inflammatory skin disorder critically depends on an appropriate activation of macrophages, with ample release of TNF-α.

In human psoriasis, the number of epithelium-lining macrophages was reported to increase in lesional skin. These macrophages can play a role in the regulation of epidermal proliferation and differentiation (van den Oord & de Wolf-Peeters, 1994); also vigorous interactions between macrophages and keratinocytes (Djemadji-Oudjil et al., 1996) may be involved in the psoriasis pathogenesis (van den Oord & de Wolf-Peeters, 1994).

Macrophages, under different conditions, secrete various pro-inflammatory cytokines: TNF-α, IL-1β, IFN-α/β, IL-6, IL-10, IL-12, and IL-18, (Willment et al., 2003) and notably, in a recent study CD68⁺ macrophages were identified as important TNF-α source in human psoriasis and upon treatment with anti-TNF-α antibody macrophage levels decreased in the plaque psoriasis, with clinical psoriasis resolution (Marble et al., 2007). In according to this finding, it is also showed that CD68⁺ macrophages as important TNF-α source in human psoriatic skin, which had distinctly decreased number and TNF-α concentration following bath-PUVA therapy (Wang et al., 2009). This was also found in a T-cell-independent mouse model, with an increase of TNF-α in macrophages (Stratis et al., 2006).

Based on literature data, an emerging model of psoriasis pathogenesis in humans suggests that dermal macrophages, activated by T-cell cytokines, produce large amounts of TNF-α, leading to skin changes (Clark & Kupper, 2006).

4.2 Dysfunction of the adaptive immune response cells

Until the 1990s, psoriasis was thought to be a disease of disordered keratinocyte proliferation and differentiation (G. G. Krueger et al., 1984) and epidermal hyperplasia was the most prominent clinical and histological feature. For this reason, the old psoriasis treatments using antimetabolites including methotrexate which limit epidermal hyperproliferation. However, successive evidence from clinical studies and, experimental models support the theory that psoriasis is a T cell-mediated inflammatory skin disease (Lew et al., 2004) affecting genetically predisposed individuals and the epidermal hyperplasia is an effect of cellular immune infiltration.

4.2.1 Role of T cells

The first evidence resulting in psoriasis being widely considered as a T cell mediated autoimmune disease came from the success in the psoriasis treatment of T cell-targeted therapies such as cyclosporine (Baker et al., 1987), tacrolimus (Jegasothy et al., 1992) or CD4-specific monoclonal antibodies (Moabs) (J. Prinz et al., 1991).

A pivotal study involved the testing of IL-2-diphtheria-toxin fusion protein in psoriasis patients (S. L. Gottlieb et al., 1995). This agent selectively depleting activated T cells that express IL-2 receptors from psoriasis skin lesions and resulted in clinical remission of psoriasis vulgaris.

Subsequently, administration of another fusion protein, cytotoxic T-lymphocyte antigen 4 (CTLA4)-antibody, was shown to reverse the clinical and cellular features of psoriasis
(Abrams et al., 1999). This agent blocks T cell co-stimulation mediated by DCs without directly deplete T cells. Its effectiveness indicated that continuing T cell co-stimulation is required to sustain psoriasis disease activity, including the excessive infiltration of T cells and DCs into the skin (Abrams et al., 2000). All these clinical results confirmed that lesion-associated T cells are central to sustaining disease activity in psoriasis.

Additional evidence highlighting the implication of T cells in psoriasis pathogenesis have been reviewed (Nestle et al., 2009) including the appearance of clonal T cells in psoriatic lesions (Menssen et al., 1995); the development of psoriasis-form phenotype within symptomless psoriatic skin after transplantation onto the xenotransplantation AGR 129 mouse model again underlines the importance of epidermal T cells in psoriasis genesis (Conrad et al., 2007).

Also, based on the findings that expansion of skin resident T cells is important in psoriasis progress in the xenotransplantation AGR mouse model, the function of tissue-specific factors in activation and expansion of resident T cells has been further explored (Conrad et al., 2007). T cells need to pass through the dermo-epidermal junction in order to go into the epidermis and collagen fibrils are an essential part of the dermo-epidermal junction. The most important basement membrane collagen is collagen IV and long-term activation of T cells results in the expression of a receptor for collagen IV, the heterodimeric integrin α1β1. It has been shown that epidermal accumulation of α1β1+ Th1 and Tc1 cells correlate with psoriasis development. Blocking α1β1 with a neutralizing Moab prevents epidermal T cell accumulation and subsequent psoriasis development in the xenotransplantation AGR mouse model. α1β1 expression can act as a checkpoint for entry of T cells into epidermis with α1β1+ epidermal T cells potentially playing an important role in psoriatic lesion formation.

In conclusion, targeting of these integrins may offer new and effective therapeutic approaches in psoriasis.

### 4.2.2 The IL-23/Th17 pathway

The IL-23/Th17 pathway is an exciting area in psoriatic pathology (Figure1) because it has led to the development of promising innovative treatments which specifically target this pathway (D’Elios et al., 2010). The development, characterization and function of Th17 cells and the role of IL-23 in Th17-cell dependent chronic inflammation in psoriasis have been recently reviewed (Di Cesare et al., 2009). Briefly, IL-23 is a heterodimeric cytokine (Oppmann et al., 2000) composed of the subunits IL-23p19 and IL-12p40 (an IL-12 subunit). Intradermal injection of IL-23 in mice resulted in the development of a psoriasis-form phenotype with histopathological features (Chan et al., 2006). IL-23 can mediate epidermal hyperplasia, acanthosis, hyperparakeratosis and orthohyperkeratosis by way of TNF-α, IL-20R2 and IL-22 (Chan et al., 2006; Zheng et al., 2007). These data are supported by findings in humans including an mRNA over-expression of IL-23p19 and IL-12p40 seen in psoriatic skin lesions, compared to uninvolved skin. Further other results indicate that IL -23 production occurs at inflammatory skin sites and is mediated by tissue-resident and/or recruited immune cells, such DCs and KCs (Piskin et al., 2006).

The pathogenic role of IL-23 in psoriasis is strongly supported by the clinical findings that anti-TNF-α agents can reduce IL-23p19 and IL-12p40 mRNA levels also the reduction of IL-
23 level caused by cyclosporin A, UV therapy and biological agents correlates to clinical improvements in psoriasis patients (A. L. Gottlieb et al., 2005; Haider et al., 2008; Piskin et al., 2004).

Transforming growth factor (TGF)-β1, IL-6 and IL-21 are all required to transform naïve T cells into cells expressing the unique lineage-specific transcription factor, RORC variant 2 and IL-23 receptors with subsequent binding of IL-23 resulting in differentiation into Th17 cells.

Th17 cells in turn produce the pro-inflammatory cytokines IL-17A, IL-17F, IL-22 and IL-26 (Langrish et al., 2005) that activate KCs leading to hyperproliferation and production of proinflammatory cytokines / chemokines, which recruit and activate other immune cells in the inflamed skin, enlarging the inflammatory response and consequently the clinical disease features. Another support for a role of the IL-23/Th17 pathway in psoriasis comes from whole genome studies showing that genetic variants of the IL-23 receptor are associated with psoriasis (Capon et al., 2007).

Regarding the clinical relevance of the IL-23/Th17 pathway, targeting the common subunit p40 of IL-12 and IL-23 demonstrated clinical improvement in psoriasis. Two anti-IL-12p40 Moabs, ustekinumab and ABT-874, have been recently developed as psoriasis cures. As we’ll see in more detail later, ustekinumab and ABT-874 are humanized IgG1 Moabs that binding to the p40 subunit of human IL-12 and IL-23, prevents interaction with IL-12Rb1. Phase I (Kauffman et al., 2004) and phase II (Kimball et al., 2008b; G. G. Krueger et al., 2007) studies supported the use of both antibodies as effective treatments for psoriasis.

The safety profile of ustekinumab in psoriasis has been evaluated in 2 phase III studies. Of these, PHOENIX I assessed the efficacy and safety of ustekinumab 45 and 90 mg administered subcutaneously at weeks 0, 4, and then every 12 weeks over 76 weeks of treatment (Leonardi et al., 2008). 67.1 % and 66.4 % of patients who received ustekinumab 45mg and 90 mg respectively, achieved PASI-75 at week 12 compared to placebo control (3.1 %). The observed adverse events were mild, non-life threatening and not significantly different from the placebo group. The most commonly reported adverse events were upper respiratory tract infections, nasopharyngitis, headache, and arthralgia. The PHOENIX II trial (Papp et al., 2008) was conducted to further assess if dosing intensification would increase the response to treatment in partial responder patients (between PASI-50 and PASI-75). It was found that dosing intensification resulted in increased clinical efficacy only in patients receiving 90mg, but not 45mg, of ustekinumab every 8 weeks (PASI-75 in 68.8 % of patients receiving 90mg every 8 weeks versus 33.3 % of patients receiving 90 mg every 12 weeks). The incidence and type of adverse events observed did not differ between PHOENIX I and II studies. Ustekinumab is also effective in the treatment of psoriatic arthritis and this study again confirmed that ustekinumab is well tolerated (A. Gottlieb et al., 2009).

4.2.3 Regulatory T cells

Regulatory T cells (Tregs) are characterized by their ability to suppress the activation and proliferation of effector T cells (CD4+/CD8+) by direct contact with antigen presenting cells (Gondek et al., 2005) or by releasing IL-10 (Annacker et al., 2003) and/or TGF-β1 (Nakamura et al., 2004) (Figure 3).
Tregs express CD4, height CD25 and Foxp3 and are about the 1-5 % of the total population of peripheral CD4+ cells.

Dysfunction of Tregs has been implicated in the pathogenesis of various autoimmune diseases such as multiple sclerosis and rheumatoid arthritis (RA) and in psoriasis; where Treg function and proliferation are both defective (Sugiyama et al., 2005). This combination may result in a failure to limit the activation and proliferation of pathogenic T cells, contributing to the ongoing inflammation seen in psoriasis; for this reason strategies that correct Treg function or increase the Treg/pathogenic T cell ratio may be potential treatments for psoriasis (Sugiyama et al., 2005). Phototherapy, for example, might induce Treg type suppressor cells as well as eliminate pathogenic T cells (Baadsgaard et al., 1990), supporting a possible role of Treg cells in protection against psoriasis.

5. Principal co-morbidities

Today we know that during the time course of psoriasis, certain conditions may appear at somewhat unpredictable time points in a progressive fashion. These so-called co-morbidities, often become manifest years after the onset of skin manifestations and are frequently observed in severe forms of psoriasis.

5.1 Psoriatic arthritis

PsA is traditionally included among common co-morbidities of psoriasis, even if it should be rather considered a component of the clinical spectrum of psoriatic disease. Skin manifestations occur before the onset of arthritis in the large majority of patients (A. B. Gottlieb et al., 2006), and in general, the prevalence of arthritis in psoriasis patients is estimated to be approximately 30% (Gisondi et al., 2005; Zachariae et al., 2002).

In PsA pathogenesis the TNF-α plays a key role, promoting osteoclastogenesis and bone resorption by stimulating the receptor-activator of NFkB, expressed in bone marrow osteoclast precursors (Abu-Amer et al., 2000; Keffer et al., 1991). Moreover, TNF-α has been noted to increase DKK-1 (dickkopf-1), a glycoprotein able to inhibit the bone apposition process by obstructing osteoblast growth (Baron & Rawadi, 2007; Diarra et al., 2007).

Numerous clinical observations support these experimental data, particularly a number of clinical trials showed a significant inhibition of joint damage in patients who underwent anti-TNF therapy, confirming the role of TNF in altered bone remodeling.

Approximately 20% of PsA patients are estimated to suffer from a severe and destructive form of arthritis, that leads to overall increased disability (D. D. Gladman et al., 1990; Queiro-Silva et al., 2003). Interestingly, different results indicate that the DMARDs (disease-modifying antirheumatic drugs) might not be able to inhibit disease progression and osteoarticular damage, even though they are generally useful in providing relief of clinical symptoms (Kana et al., 2003).

There is also convincing evidence of increased mortality in PsA patients, which seems to be related to disease activity, characterized by high erythrosedimentation rate, high medication level, and significant radiological damage at early patient visits (D. D. Gladman et al., 1998). Fortunately, as we shall see later, the mortality in PsA patients has gradually improved by using the biological drugs (Ali et al., 2007).
5.2 Inflammatory bowel disease (IBD)

IBD commonly refers to ulcerative colitis (UC) and Crohn’s disease (CD), which are chronic inflammatory diseases of the gastrointestinal tract with unknown etiology. UC and CD have significant clinical differences, however, both diseases share similar pathogenic mechanisms and many extra-intestinal manifestations, and frequently respond to the same treatments.

Many data indicate a stringent correlation between CD and psoriasis (Najarian & A. B. Gottlieb, 2003). Firstly, CD patients have been found to have a seven-fold higher risk of developing psoriasis than control subjects (Mrowietz et al., 2006). This association may be related to the following observations: a) it has been shown that TNF-α has a key role in both conditions, valuing the hypothesis of common inflammatory pathways. This point has been further supported by the therapeutic efficacy of anti-TNF-α antibodies; b) genetic evidences, such as polymorphisms in the TNF-α promoter region and the close position of the susceptibility loci, link psoriasis to CD (Najarian & A. B. Gottlieb, 2003). In particular, a recent study demonstrated a significant association between CD and the IL-23 receptor gene (Duerr et al., 2006) and, as reported previously, IL-23 /IL-17 pathway is involved in psoriasis pathogenesis (Blauvelt, 2008; Rizzo et al., 2011).

On the other hand, the association between psoriasis and UC has been described in only in recent studies, even if the first studies regarding this connection trace back to the 60s and early 70s (Brewerton et al., 1974; McEwen et al., 1971). Most recently, Cohen et coll. (Cohen et al., 2009), in a case-control study with 12,502 psoriasis patients, demonstrated that even though not as high as CD (odds ratio 2.49), UC association is statistically significant and far from being negligible (odds ratio 1.64). This often undervalued correlation is biologically conceivable because chronic systemic inflammation and TNF-α constitute core features of UC, as well as psoriasis (Torres & Rios 2008).

5.3 Metabolic Syndrome (MS) and Cardiovascular Diseases (CVD)

Different overlapping guidelines have been proposed to define the MS: the cardiometabolic risk factors of obesity, impaired glucose tolerance (or type 2 diabetes), insulin resistance, dyslipidemia, and hypertension (Alberti et al., 2006; Grundy et al., 2005; Johnson & Weinstock, 2006). Just like psoriasis, MS is characterized by a pro-inflammatory state, characterized by a complex cytokines network.

In response to various metabolic signals the adipose tissue release the adipokines that modulate flogosis, lipid metabolism, and insulin sensitivity. A cluster of these adipokines is represented by pro-inflammatory cytokines (TNF-α, IL-8 and IL-6) whose overproduction drives the psoriasis pathogenesis, as well as of certain basic features of MS like insulin resistance and diabetes (Arican et al., 2005; Nickoloff & Nestle, 2004; Rondinone, 2006). Consistent with this common pathophysiology, different studies have demonstrated that psoriasis patients show an increased risk of developing the metabolic syndrome (Henseler & Christophers, 1995; Neimann et al., 2006).

The multiple conditions that constitute the MS could very well be the main reasons for CVD in psoriasis patients.
However, in various studies involving patients with psoriasis, the latter was identified as an independent risk factor for myocardial infarction regardless of the presence of the complete MS and an independent risk factor for coronary artery calcification (Gelfand et al., 2006).

Indeed, as of today there is forceful evidence that psoriasis, much like other systemic pro-inflammatory conditions (e.g. RA, SLE), may predispose to an increased CVD risk, following a nontraditional pathway to atherogenesis and premature vascular damage (Kimball et al., 2008c; Saphiro et al., 2007).

In conclusion, basic inflammatory activity in psoriasis could act independently of traditional risk factors, MetS included, and can increase the risk of CVD through its own underlying biological mechanisms (inflammation-driven atherogenesis).

<table>
<thead>
<tr>
<th>Cell Types</th>
<th>Biological Effects</th>
<th>Clinical Consequences</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Leukocytes</strong></td>
<td>Activation/maturation</td>
<td>↑ Inflammation</td>
</tr>
<tr>
<td></td>
<td>↑ inflammatory</td>
<td>Endothelial injury</td>
</tr>
<tr>
<td></td>
<td>cytokine/expression</td>
<td>Epidermal Proliferation</td>
</tr>
<tr>
<td></td>
<td>ROS release</td>
<td></td>
</tr>
<tr>
<td><strong>Endothelial cells</strong></td>
<td>Suppression of precursor cells/apoptosis</td>
<td>↑ Angiogenesis</td>
</tr>
<tr>
<td></td>
<td>↑ expression of adhesion molecules</td>
<td>↑ leukocytes recruitment</td>
</tr>
<tr>
<td></td>
<td>↑ release of VEGF</td>
<td>Endothelial dysfunction</td>
</tr>
<tr>
<td></td>
<td>Impaired NO Bioavailability</td>
<td>Hemostasis impairment</td>
</tr>
<tr>
<td></td>
<td>Induction of TF expression</td>
<td></td>
</tr>
<tr>
<td><strong>Osteoclast precursors</strong></td>
<td>↑ RANKL expression (↑osteoclast maturation/activation)</td>
<td>Bone resorption promotion</td>
</tr>
<tr>
<td></td>
<td>↑ DKK-1 level (↓ osteoclast development)</td>
<td>Bone apposition inhibition</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Condrocytes/Synoviocytes</strong></td>
<td>Apoptosis</td>
<td>Articular erosion</td>
</tr>
<tr>
<td></td>
<td>↑ Metalloproteinase synthesis</td>
<td></td>
</tr>
<tr>
<td><strong>Adipocytes</strong></td>
<td>Dysregulation of lipid and glucose metabolism</td>
<td>Disadvantageous metabolic response to injury and infection</td>
</tr>
<tr>
<td></td>
<td>↑ circulating levels of FFA and LDL</td>
<td>↑ in traditional CV risk factors</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hepatocytes</strong></td>
<td>Induction of IL-6</td>
<td>Raised CRP serum levels</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CRP-induced vascular dysfunction</td>
</tr>
<tr>
<td><strong>Neural cells</strong></td>
<td>Modulation of cell proliferation NGF-induced</td>
<td>Neurogenic inflammation</td>
</tr>
</tbody>
</table>

↑ = Increase; ↓ = decrease; CRP = C-reactive protein; CV = Cardiovascular; DKK-1 = Dickkopf-1; LDL = Low-density lipoproteins; NGF = Nerve growth factor; NO = Nitric oxide; RANKL = Receptor-Activator of NFkappaB ligand; ROS = Reactive oxygen species; TF = Tissue Factor; VEGF = Vascular endothelial growth factor.

Table 1. Biological effects and clinical consequences of TNF-α stimulation in different cells
Recently, some studies have also shown that in psoriasis patients, the increased risk for myocardial infarction varies by age (higher in younger individuals) and disease severity (higher in severe forms) (Gelfand et al., 2006; Kremers et al., 2007; Mallbris et al., 2004). As such, a young patient with severe psoriasis is burdened by a CVD risk comparable with what is seen in the presence of traditional risk factors such as diabetes and hypertension.

Moreover, a variety of data indicates that psoriasis and CVD (mostly atherosclerosis) share common pathogenic features: both Th1 mediated, with an up-regulation of Th1 cytokines (TNF-α, IFN-γ) and a systemic expression of adhesion molecules, neoangiogenesis factors, and superantigens, these latter potentially able to activate the T cells (Biedermann et al., 2004; Ettehadi et al., 2004; Gudjonsson et al., 2004). The table 1 summarizes the consequences of the TNF-α over-expression in promoting inflammatory conditions such as psoriasis and atherogenesis.

Overlapping of genetic susceptibility loci between psoriasis and atherosclerosis is also worth mentioning, even though its role has yet to be fully understood (Becker et al., 1998).

Lastly, the two conditions also show similar histological aspects, mainly involving T cells, macrophages, mast cells and connective tissue matrix. (Nickoloff et al., 2007a; Nickoloff et al., 2007b).

Alongside the similar pathogenesis, other indirect factors might be responsible for psoriasis-CVD association; in fact some authors have found that a number of conventional systemic psoriasis treatments (e.g. methotrexate, acitretin, cyclosporine) might increase the effects of specific CVD risk factors (Katz et al., 1994; Strober & Menon, 2005; Taler et al., 1999).

6. Disease evaluation

To assess the severity of psoriasis and PsA (baseline/in response to treatment), a number of tools are now available, of which the Psoriasis Activity and Severity Index (PASI) is the most frequently used (Fredriksson & Pettersson, 1978). The PASI combines assessments of the extent of body surface involvement in four anatomical regions (head, trunk, arms and legs) and the severity of desquamation, erythema and plaque induration (thickness) in each region, yielding an overall score of 0 (no psoriasis) to 72 (severe psoriasis) (Fredriksson & Pettersson, 1978). PASI 75 is defined as a 75% reduction in PASI compared with baseline, instead a PASI score of >10 is defined as moderate to severe disease, necessitating systemic therapy (PUVA, UVB 311, MTX, cyclosporin A or biological drugs) (Pathirana et al., 2009)

An additional tool to assess the psoriasis severity is the physician’s global assessment (PGA). The PGA takes into account the involvement of the body surface area, induration, scaling and erythema and grades the patient’s psoriasis overall, relative to baseline, as 1 (clear), 2 (excellent), 3 (good), 4 (fair), 5 (poor) or 6 (worse) (Pathirana et al., 2009).

In trials investigating patients with PsA, the American College of Rheumatology Criteria (ACR) are most commonly used. The ACR clinical response criteria are defined as percentage reduction [20% (ACR 20), 50% (ACR50) and 70% (ACR 70)] in tender and swollen joint counts and in 3 of the, remaining, 5 ACR core items (patient and physician global assessments, pain, disability and an acute phase reactant) (Montecucco, 2006; Radtke et al., 2009).
A supplementary tool to evaluate clinical remission in psoriatic patients is the Disease Activity Score (DAS) comprising the number of swollen and tender joints, the erythrocyte sedimentation rate and the general health of the patient (measured on a visual analogue scale) (Montecucco, 2006). The DAS measures 44 swollen joints, whereas the modified DAS 28 measures only 28 swollen and tender joints (Prevo et al., 1995). The effect of psoriasis on the patient's quality of life is measured by the 10-item Dermatology Life Quality Index (DLQI) questionnaire. DLQI scores range from 0 (not at all) to 30 (very much) (Pathirana et al., 2009).

7. Biological drugs

Biological therapies for the treatment of psoriasis are defined by their mode of action and are classified into 3 groups, the inhibitors of TNF-α (adalimumab, certolizumab, etanercept, golimumab, and infliximab), the T-cell modulating agents (such as alefacept) and the inhibitors of IL-12 and IL-23 (ustekinumab and briakinumab).

7.1 TNF-α inhibitors

The TNF-α inhibitors adalimumab, etanercept and infliximab have been approved by the FDA and EMEA for psoriasis and PsA treatment; they have been reviewed quite extensively in the past and the table 2 summarizes the clinical outcome for primary endpoints (e.g. PASI and ACR) in randomized controlled studies.

In this chapter, instead will focus on the new TNF-α blockers such as golimumab and certolizumab (Mössner et al., 2008; Pathirana et al., 2009).

<table>
<thead>
<tr>
<th>Drug</th>
<th>Disease</th>
<th>Trial Type</th>
<th>Treatment (n° of patients)</th>
<th>Major Results</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adalimumab</td>
<td>Psoriasis</td>
<td>12-week RDBPC OLE until week 60</td>
<td>A 40 mg weekly (50) A 40 mg eow (46) Placebo (52)</td>
<td>PASI 75 at week 12: 80 PASI 75 at week 12: 53 PASI 75 at week 12: 4</td>
<td>Gordon et al., 2006 J Am Acad Dermatol 55: 598–606.</td>
</tr>
<tr>
<td>Adalimumab (REVEAL)</td>
<td>Psoriasis</td>
<td>16-week RDBPC OLE until week 52</td>
<td>A 40 mg eow (814) Placebo (398)</td>
<td>PASI 75 at week 16: 71 PASI 75 at week 16: 7</td>
<td>Menter et al., 2008 J Am Acad Dermatol 58: 106–115.</td>
</tr>
<tr>
<td>Adalimumab (CHAMPION)</td>
<td>Psoriasis</td>
<td>16-week RDBPC</td>
<td>A 40 mg eow (108) MTX (110) Placebo (53)</td>
<td>PASI 75 at week 16: 80 PASI 75 at week 16: 36 PASI 75 at week 16: 19</td>
<td>Saurat et al., 2008 Br J Dermatol 158: 558–566.</td>
</tr>
<tr>
<td>Adalimumab (ADEPT)</td>
<td>Psoriasis arthritis</td>
<td>24-week RDBPC OLE</td>
<td>A 40 mg eow (151) Placebo (162)</td>
<td>ACR 20 at week 12: 58 ACR 20 at week 12: 58</td>
<td>Mease et al., 2005 Arthritis Rheum</td>
</tr>
<tr>
<td>Adalimumab</td>
<td>Psoriasis arthritis</td>
<td>12-week RDBPC</td>
<td>OLE until week 24</td>
<td>OLE A (281)</td>
<td>week 12: 14</td>
</tr>
<tr>
<td>------------</td>
<td>---------------------</td>
<td>----------------</td>
<td>----------------</td>
<td>-------------</td>
<td>-------------</td>
</tr>
<tr>
<td>Etanercept</td>
<td>Psoriasis</td>
<td>12-week RDBPC</td>
<td>E 25 mg twice weekly (57)</td>
<td>Placebo (55)</td>
<td>PASI 75 at week 12: 30</td>
</tr>
<tr>
<td>Etanercept</td>
<td>Psoriasis RDBPC</td>
<td>E 25 mg twice weekly (160)</td>
<td>Placebo (193)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etanercept CONSORT</td>
<td>Psoriasis RDBPC</td>
<td>E 25 mg twice weekly (162)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etanercept</td>
<td>Psoriasis</td>
<td>12-week RDBPC</td>
<td>E 50 mg twice weekly (164)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etanercept</td>
<td>Psoriasis</td>
<td>12-week RDBPC</td>
<td>E 50 mg twice weekly (311)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etanercept</td>
<td>Psoriasis arthritis</td>
<td>12-week RDBPC</td>
<td>E 25 mg twice weekly (30)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Etanercept</td>
<td>Psoriasis arthritis</td>
<td>24-week RDBPC</td>
<td>E 25 mg twice weekly (101)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Gladman et al., 2007
Mease et al., 2009
Genovese et al., 2007
J Rheumatol 34: 1040–1050.
Gottlieb et al., 2003
Arch Dermatol 139: 1563–1570.
Papp et al., 2005
Leonardi et al., 2003
Tyring et al., 2006
Mease et al., 2000
Mease et al., 2004
<table>
<thead>
<tr>
<th>Drug</th>
<th>Indication</th>
<th>Study Design</th>
<th>Dose</th>
<th>Efficacy Parameters</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infliximab</td>
<td>Psoriasis</td>
<td>SPIRIT</td>
<td>I 3 mg·kg⁻¹ (99)</td>
<td>PASI 75 at week 10: 72</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RDBPC</td>
<td>Placebo (51)</td>
<td>PASI 75 at week 10: 6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I 5 mg·kg⁻¹ (99)</td>
<td>PASI 75 at week 10: 88</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I 5 mg·kg⁻¹ (99)</td>
<td>PASI 75 at week 10: 6</td>
</tr>
<tr>
<td>Infliximab</td>
<td>Psoriasis</td>
<td>EXPRESS I</td>
<td>I 5 mg·kg⁻¹ (301)</td>
<td>Placebo (77)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RDBPC</td>
<td>Placebo (301)</td>
<td>PASI 75 at week 10: 80</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I 10 mg·kg⁻¹ (11)</td>
<td>PASI 75 at week 10: 73</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo (11)</td>
<td>PASI 75 at week 10: 3</td>
</tr>
<tr>
<td>Infliximab</td>
<td>Psoriasis</td>
<td>EXPRESS II</td>
<td>I 3 mg·kg⁻¹ (311)</td>
<td>Placebo (208)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RDBPC</td>
<td>Placebo (208)</td>
<td>PASI 75 at week 10: 70</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I 5 mg·kg⁻¹ (314)</td>
<td>PASI 75 at week 10: 76</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo (11)</td>
<td>PASI 75 at week 10: 2</td>
</tr>
<tr>
<td>Infliximab</td>
<td>Psoriasis</td>
<td>IMPACT</td>
<td>I 5 mg·kg⁻¹ (52)</td>
<td>Placebo (52)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RDBPC</td>
<td>Placebo (52)</td>
<td>ACR 20 at week 16: 65</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I 5 mg·kg⁻¹ (52)</td>
<td>ACR 20 at week 16: 10</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo (52)</td>
<td>ACR 20 at week 16: 10</td>
</tr>
<tr>
<td>Infliximab</td>
<td>Psoriasis</td>
<td>IMPACT II</td>
<td>I 5 mg·kg⁻¹ (100)</td>
<td>Placebo (100)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RDBPC</td>
<td>Placebo (100)</td>
<td>ACR 20 at week 24: 54</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>I 5 mg·kg⁻¹ (100)</td>
<td>ACR 20 at week 24: 16</td>
</tr>
<tr>
<td>Golimumab</td>
<td>Psoriasis</td>
<td>GO-REVEAL</td>
<td>G 50 mg q4 wks (146)</td>
<td>Placebo (113)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RDBPC</td>
<td>Placebo (113)</td>
<td>PASI 75 at week 14: 40</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>G 100 mg q4 wks (146)</td>
<td>PASI 75 at week 14: 58</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo (113)</td>
<td>PASI 75 at week 14: 3</td>
</tr>
<tr>
<td>Golimumab</td>
<td>Psoriasis</td>
<td>GO-REVEAL</td>
<td>G 50 mg q4 wks (146)</td>
<td>Placebo (113)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>RDBPC</td>
<td>Placebo (113)</td>
<td>ACR 20 at week 14: 51</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>G 100 mg q4 wks (146)</td>
<td>ACR 20 at week 14: 45</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo (113)</td>
<td>ACR 20 at week 14: 9</td>
</tr>
</tbody>
</table>

A= Adalimumab; E = Etanercept; I = Infliximab; G = Golimumab; OLE = Open Level Extension; q4 wks = every 4 weeks; RDBPC = Randomized Double-Blind Placebo Controlled Trial

Table 2. Efficacy of anti-TNF-α in the treatment of psoriasis and psoriasis arthritis
Up to now, treatment with MoaB anti-TNF-α has proven to be effective and relatively safe in patients with psoriasis and PsA (Lima et al., 2009).

Since TNF-α has showed an osteoclast stimulating effect, alongside being synergic with DKK-1 in reducing osteoblasts maturation, anti-TNF-α drugs should improve PsA-related bone altering processes, as confirmed by significant inhibition of radiographic progression during treatment with etanercept or infliximab (Antoni et al., 2008; Mease et al., 2006b; van der Heijde et al., 2007).

Equally importantly, anti-TNF-α therapy might have a preventive effect on PsA overlapping in psoriasis patients. In fact, in a case-control study, Gisondi group (Gisondi et al., 2008) has demonstrated that lower limb enthesopathy can be documented in asymptomatic psoriasis patients without any clinical sign of arthropathy. Similar findings were reported in the past concerning entheseal abnormalities (De Filippis et al., 2005) and increased Achilles tendon thickness (Özcakar et al., 2005); all of which were detected in asymptomatic patients.

Different evidences have proved that anti-TNF-α treatments infliximab and adalimumab are effective in controlling gut inflammation, whereas etanercept is not (Bosani et al., 2009).

There are reports of CD development in patients with ankylosing spondylitis or PsA (Song et al., 2008) and treated with etanercept. However, it is well-known that such patients are burdened with a high risk of chronic IBD development. It is therefore hard to assess whether these cases of CD were really a consequence of anti-TNF-α therapy or rather a coincidental event in predisposed patients.

The reason for the discordant effect of anti-TNF-α treatments on IBD probably lies in different pharmacodynamic features of these drugs, and a number of hypotheses have been expressed in this regard.

Firstly, it has been noted that etanercept, unlike anti-TNF-α Moabs, doesn’t induce apoptosis of activated lymphocytes in CD patients (Van den Brande et al., 2003). Given the existing results, it is reasonable to conclude that etanercept has no potential to control or to prevent gut inflammation and hence IBD appearance. A preventive role of anti-TNF-α Moabs against the IBD development in susceptible psoriasis patients cannot be rule out considering the effectiveness of these drugs in both conditions.

About the effects of anti-TNF-a Moabs in MS and CVD, studies regarding the consequence on blood lipids have shown unclear results. A study of RA patients reported a significant decreased atherogenic index of low-density lipoprotein (LDL)/high-density lipoprotein (HDL) ratio after 6 months of therapy with anti-TNF-a (Spanakis et al., 2006); another showed increased HDL levels and reduced C-reactive protein (CRP) and IL-6 levels after 2 weeks (Popa et al., 2005). In contrast, in some cases anti-TNF-a therapy has resulted in a pro-atherogenic effect in RA and PsA patients, with increase of LDL/HDL ratio and triglycerides levels (Dahlqvist et al., 2004). Another study demonstrated a sudden reduction in HDL levels the day after infliximab infusion, but without any significant variation in the HDL profile (Irace et al., 2004).

No conclusions can be drawn from these inconsistent findings regarding long-term clinical outcomes. As a consequence, many authors seem to agree on the fact that despite the prominent role of TNF-α on lipid regulation, the emerging efficacy of anti-TNF-α therapy
<table>
<thead>
<tr>
<th>Anti-TNF-a therapy</th>
<th>Frequent side effects</th>
<th>Rare severe side effects</th>
<th>Reference</th>
</tr>
</thead>
</table>
| **Adalimumab**     | • Upper respiratory tract infections  
|                     | • Injection site reactions  
|                     | • Headache               | • Severe/ Opportunistic infections  
|                     |                       | • Reactivation/progression of TBC | Pathirana *et al.*, 2009  
|                     |                       | • Onset/exacerbation of CNS demyelinating disorders (e.g. Multiple Sclerosis) | *J Eur Acad Dermatol Venerol* 23 (Suppl. 2): S5–70.  
|                     |                       | • Increased risk of cancer (e.g. Lymphoma) | Smith *et al.*, 2009  
|                     |                       | • Exacerbation of congestive heart failure | |
|                     |                       | • Vasculitis              | |
|                     |                       | • Aplastic anaemia        | |

| **Etanercept**     | • Upper respiratory tract infections  
|                     | • Injection site reactions  
|                     | • Pruritus               | • Severe/ Opportunistic infections  
|                     |                       | • Reactivation/progression of TBC | Pathirana *et al.*, 2009  
|                     |                       | • Onset/exacerbation of CNS demyelinating disorders (e.g. Multiple Sclerosis) | *J Eur Acad Dermatol Venerol* 23 (Suppl. 2): S5–70.  
|                     |                       | • Increased risk of cancer (e.g. Lymphoma) | Smith *et al.*, 2009  
|                     |                       | • Exacerbation of congestive heart failure | |
|                     |                       | • Vasculitis              | |
|                     |                       | • Aplastic anaemia        | |

| **Infliximab**     | • Upper respiratory tract infections  
|                     | • Acute infusion reaction: fever, chills, nausea  
|                     | • Headache               | • Severe/ Opportunistic infections  
|                     | • Pruritus               | • Reactivation/progression of TBC | Pathirana *et al.*, 2009  
|                     | • Urticaria              | • Onset/exacerbation of CNS demyelinating disorders (e.g. Multiple Sclerosis) | *J Eur Acad Dermatol Venerol* 23 (Suppl. 2): S5–70.  
|                     | • Elevated transaminases | • Increased risk of cancer (e.g. Lymphoma) | Smith *et al.*, 2009  
|                     |                       | • Exacerbation of congestive heart failure | |
|                     |                       | • Vasculitis              | |
|                     |                       | • Pancytopenia            | |

Table 3. Overview of side effects of most prescribed anti-TNF-a treatments in patients with psoriasis
on CV morbidity and mortality is likely independent of the induced blood lipid variations (Soubrier et al., 2008).

Results derived from studies about the effects of anti-TNF-α drugs on insulin resistance in psoriasis patients, appear to show an improvement in insulin sensitivity (Marra et al., 2007). This outcome seems to confirm the beneficial effects of anti-TNF-α Moabs already documented in many RA studies (Huvers et al., 2007; Yazdani-Biuki et al., 2004). In particular, infliximab has proved capable of enhancing insulin sensitivity after the infusion to up to one year (Huvers et al., 2007). Lastly, there have been few isolated cases of psoriasis patients with diabetes developing unpredictable hypo- or hyperglycemia after commencing treatment with TNF inhibitors (Boulton & Bourne, 2007; Wu & Tsai 2008).

In the table 3 are reported the side effects of adalimumab, etanercept and infliximab treatment in psoriasis patients.

### 7.1.1 Golimumab (CNTO148)

Golimumab is a human immunoglobulin G1K Moab binding both soluble and transmembrane forms of TNF-α, thereby neutralizing their bioactivity by blocking the interaction with receptor (Kavanaugh et al., 2009; Xu et al., 2009).

In a study with 337 patients, the pharmacokinetics of subcutaneously administered golimumab (50 or 100 mg every 4 weeks) were analyzed (Xu et al., 2009) and the following golimumab pharmacokinetic parameters were found: apparent clearance = 1.38 ± 0.04 L per day, apparent volume of distribution = 24.9 ± 1.04 L and absorption rate constant = 0.908 ± 0.121 per day. Significant covariants on apparent clearance were identified as body weight, baseline C-reactive protein level and smoking habits. However, only body weight was found to be a significant covariant on apparent volume of distribution. In addition, golimumab concentrations in patients (50 mg golimumab every 4 weeks) not receiving MTX were 30% lower as compared with patients receiving MTX (Xu et al., 2009). So far, no possible explanation for the different effects of MTX on the serum golimumab concentrations has been provided (Xu et al., 2009).

A randomized, double-blind, placebo-controlled phase III multicenter study was conducted to evaluate the safety and efficacy of golimumab from week 0 to 20 in 405 patients with active PsA (Kavanaugh et al., 2009).

Active PsA was defined as at least three swollen joints and three tender joints as well as active plaque psoriasis with a qualifying lesion of at least 2 cm in diameter. Concomitant MTX, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids were permitted at stable doses.

A significant reduction in PASI 75 among patients receiving golimumab 50 or 100 mg at week 14 (40 and 58%) was observed when compared with patients receiving placebo (3%). PASI 75 scores in patients with golimumab (50 and 100 mg) further improved at week 24 in both golimumab groups (56 and 66%), whereas only 1% of patients in the placebo group reached a PASI 75 (Kavanaugh et al., 2009).

Golimumab significantly ($P < 0.001$) improved signs and symptoms of PsA compared with patients treated with placebo (Kavanaugh et al., 2009). An ACR 20 response at week 14
could be achieved in 51% of patients treated with golimumab 50 mg and in 45% of patients receiving golimumab 100 mg versus only 9% in the placebo group. At week 24, an ACR 20 response was observed in 52% in the golimumab 50-mg group and in 61% in the golimumab 100-mg group versus 12% in the placebo group ($P < 0.001$). ACR 50 and 70 responses were also significantly higher in both golimumab groups than in the placebo group. At week 104, 91.4% of patients in the 50-mg group and 73.1% in the 100-mg group achieved an ACR 20 (Kavanaugh et al., 2009). A good or moderate DAS 28 response was significantly ($P < 0.001$) more often achieved in the golimumab 50 and 100-mg recipients than in the placebo group at week 14 (66 and 67% vs. 24%) and at week 24 (64 and 78% vs. 24%) (Kavanaugh et al., 2009). Assessment of physical function and health-related quality of life were measured by the Health Assessment Questionnaire (HAQ) and Short Form 36 Health Survey (SF-36) and significantly improved in both golimumab groups compared with the placebo group ($P < 0.001$ for HAQ and SF-36 at all comparisons at week 24). Thus, in this study golimumab improved significantly the clinical signs and symptoms of PsA as well as the physical function and quality of life (Kavanaugh et al., 2009).

About the safety of this treatment, Kavanaugh and coll. (Kavanaugh et al., 2009) reported that 8.6% of patients treated with golimumab shown a serious adverse event up to week 104: serious infectious adverse events comprised sepsis/cholecystitis and abscess formation. About the cancers registered: one basal cell carcinoma, one colon cancer and one small lung cell carcinoma in the golimumab 50-mg group. In the golimumab 100-mg group, three basal cell carcinomas, one prostate cancer and one small lung cancer occurred.

As for adverse events, infections of the upper respiratory tract and nasopharyngitis were most frequently reported.

### 7.1.2 Certolizumab pegol (CDP870)

Certolizumab pegol, a pegylated Fab-9 fragment of a humanized anti-TNF-α Moab, has been approved for the treatment of patients with CD (Bourne et al., 2008) and it has also been investigated in RA patients (Barnes & Moots, 2007).

It binding to TNF-α, blocks the interaction with specific receptors. Whereas adalimumab, etanercept and infliximab contain an IgG1 Fc region, which can induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC), certolizumab lacking this Fc region, isn’t able of inducing ADCC and CDC (European Medicines Agency [EMEA], 2008).

Pharmacokinetic analysis in the CDP870 trial showed a bioavailability of 85% (EMEA, 2008). Peak plasma concentrations were attained between 54 and 171 h after subcutaneous injection. The mean serum concentration (Cmax) after the subcutaneous administration of 400-mg certolizumab ranged from 46.3 ± 13.1 to 49.5 ± 8.2 mg·mL⁻¹. An increase of Cmax and area under the curve (AUC) was observed with higher doses in a dose-proportional manner. The half-life of certolizumab was found to be approximately 14 days (EMEA, 2008).

Certolizumab pegol has been investigated in patients with moderate to severe psoriasis. In a phase II trial, patients were randomized to receive certolizumab pegol 200 mg, 400 mg or placebo subcutaneously every 2 weeks up to week 12. At week 12, significantly more patients receiving certolizumab pegol 200 or 400 mg achieved PASI 75 than in the placebo...
The most frequently reported adverse events comprised headache, nasopharyngitis and pruritus. The frequency of adverse events was similar across all three groups. However, serious adverse events were more common in the 400-mg group (7.0%) than in the 200-mg group (3.3%) and in the placebo-group (1.7%) (Ortonne et al., 2007). According to the data from the phase II study, PASI 75 results and side effects were comparable with those observed in patients treated with the approved TNF-α blockers adalimumab and infliximab. So far, no phase III studies or studies in patients with PsA have been conducted.

7.2 T-cell modulators

In 2003, alefacept and efalizumab were the first biological agents to be approved by the Food and Drug Administration (FDA) for the treatment of psoriasis (Pathirana et al., 2009). In the European Union, only efalizumab was approved for the psoriasis therapy (Pathirana et al., 2009). In 2009, efalizumab was withdrawn from the market in Europe and the United States (EMEA, 2009; Food and Drug Administration [FDA], 2009).

7.2.1 Alefacept

Alefacept, a recombinant dimeric fusion protein, is made up of the terminal portion of leukocyte function antigen-3 (LFA-3). It binds to extracellular human CD2 and the Fc portion of human immunoglobulin IgG1 (Sugiyama et al., 2008). Alefacept blocks signalling between LFA-3 on antigen presenting cells and the CD2 molecule on T cells (primarily CD45RO+).

Subsequently, the activation and proliferation of CD45RO+ T cells, which account for approximately 75% of T lymphocytes in psoriatic lesions, are inhibited. Furthermore, alefacept decreases the number of pathogenic T cells by binding CD2 on CD45RO+ T cells to the FcγIII receptor on natural killer cells, resulting in granzyme-mediated apoptosis of T cells (Gordon et al., 2003; Sobell et al., 2009; Sugiyama et al., 2008). Using a dosage of 15 mg alefacept administered intramuscularly QW, PASI 75 scores at week 12 were found to range between 21 and 35% (Gordon et al., 2003; Pathirana et al., 2009; Sugiyama et al., 2008). Recently, patients receiving alefacept in combination with MTX were shown to improve significantly in ACR 20 at week 24 compared with patients treated with MTX and placebo alone (54% vs. 23%; \( P < 0.001 \)) (Mease et al., 2006a).

7.3 IL-12/IL-23 antagonists

Briakinumab and ustekinumab are both IL-12/IL-23 antagonists. Whereas briakinumab is currently under investigation for the psoriasis treatment in several phase III studies, ustekinumab was recently approved by the EMEA for the therapy of chronic plaque psoriasis.

7.3.1 Briakinumab (ABT874)

Briakinumab is a recombinant fully human, IgG1 Moab targeting the shared p40 subunit of IL-12 and IL-23 (Kimball et al., 2008b). It binds to soluble forms of IL-12 and IL-23, leading to a decreased secretion of pro-inflammatory cytokines: IL-12, IL-6, IFN-γ and TNF-α, as shown in CD patients (Ding et al., 2008).
In a phase I trial with 64 healthy controls, the pharmacokinetics of briakinumab (0.1–5.0 mg kg\(^{-1}\) subcutaneously or intravenously) were evaluated. A linear relationship between the Cmax and AUC (concentration-time) was found with increasing doses. The terminal phase half-life time was about 9 days. No dose dependency was found for the volume distribution at steady state and the clearance of the drug. Subcutaneous and intramuscular application achieved an absolute bioavailability of 42 and 63% respectively (Ding et al., 2008).

A phase II study with briakinumab was conducted (Kimball et al., 2008b) in patients with psoriasis. Patients were randomized in groups of 30 to receive either only one dose of briakinumab 200 mg at week 0, 100 mg briakinumab every other week for 12 weeks, 200 mg weekly for 4 weeks, 200 mg every other week for 12 weeks and 200 mg every week for 12 weeks, or placebo respectively (Kimball et al., 2008b).

PASI 75 was significantly \((P < 0.001)\) more often reached in patients in all five briakinumab treatment groups (63, 93, 90, 93, and 90% respectively) compared with the placebo group (3%). Statistically significant improvement to briakinumab therapy was rapid and could be registered in the briakinumab groups as early as at week 1. During the 12-week period, improvement could be sustained in briakinumab-treated patients even for patients in the briakinumab 200 mg x 1 and 200 mg x 4 dosage groups.

Besides injection site reactions, other common side effects the trial study comprised nasopharyngitis and upper respiratory infections. In addition, non-infectious serious adverse events reported in this study included costal chondritis in one patient. Significantly more patients in the briakinumab groups (36%) experienced adverse events compared with the placebo group (10%) (Kimball et al., 2008b).

### 7.3.2 Ustekinumab (CNT01275)

Ustekinumab is a human monoclonal antibody binding with high affinity to the p40 subunit of IL 12 and IL 23 and therefore inhibiting the binding to specific receptor (IL-12Rb1) expressed on various cells.

In a phase I study, patients with constant 70% PASI improvement at weeks 8, 12 and 16 shown significant decreases in mRNA expression of different cytokines (IL-8, IL-18 and IFN-\(\gamma\)) as early as week 1 \((P < 0.05)\), whereas, in patients without PASI improvement, no significant reduction of cytokine mRNA expression was observed (Wittig, 2007).

The pharmacokinetics of ustekinumab were assessed in different studies (A. B. Gottlieb et al., 2007; Kaufmann et al., 2004; Wittig, 2007): after a single subcutaneous injection, ustekinumab was slowly absorbed into the systemic circulation (mean Tmax about 12 days) and was afterwards slowly eliminated from the circulation (mean t1/2 around 20 days) (A. B. Gottlieb et al., 2007; Wittig, 2007).

The terminal half-life \((t1/2)\) was dose dependent and was found to range from 14.9 ± 4.6 days (0.27 mg kg\(^{-1}\) dose group) to 28.6 ± 9.3 days (2.7 mg kg\(^{-1}\) dose group) (A. B. Gottlieb et al., 2007). Similar results were also observed for \(t1/2\) by Kaufman (Kaufmann et al., 2004), ranging from 18.5 ± 3.6 in the 0.3-mg group to 25.9 ± 3.7 in the 1.0-mg group. An increase of Cmax and AUC was observed with superior dosages (A. B. Gottlieb et al., 2007; Kaufmann et al., 2004).
In the clinical trial conducted by Kaufman (Kaufmann et al., 2004), 18 psoriasis patients were enrolled in four dose groups: 0.1, 0.3, 1.0 and 5.0 mg per kg to assess the clinical response and the safety of a single intravenous administration of ustekinumab. At week 12, PASI 75 was reached in 25, 50, 60 and 100% of patients respectively. In patients responding to ustekinumab treatment, the expression of pro-inflammatory cytokines and chemokines IFN-γ, CXCL-8, CCR2, TNF-α, IL-12p40 and IL-23p19 subunits was decreased, compared with baseline levels (Reddy et al., 2007; Toichi et al., 2006).

In a second double-blind, placebo-controlled study, patients were randomized to receive either a single subcutaneous injection of 0.27, 0.675, 1.35 or 2.7 mg·kg⁻¹ ustekinumab or placebo (A. B. Gottlieb et al., 2007). For a second time, patients treated with ustekinumab showed a dose-dependent improvement of their psoriasis. PASI 75 was achieved in 60% of the 0.27 mg·kg⁻¹ group, 100% in the 0.675 mg·kg⁻¹ group, 50% in the 1.35 mg·kg⁻¹ group and 100% in the 2.7 mg·kg⁻¹ group, but in none of the patients receiving placebo during the whole study period.

Krueger (G. G. Krueger et al., 2007) evaluated in a double-blind, placebo controlled trial, four subcutaneous dosing regimens of ustekinumab in patients with psoriasis; 320 patients were randomized to receive one of the following treatment regimens: one 45-mg dose, one 90-mg dose, four weekly 45-mg doses and four weekly 90-mg doses of ustekinumab or placebo. The primary endpoint of the study was a 75% improvement in the PASI at week 12. PASI 75 was achieved in 52% of patients receiving ustekinumab 45 mg, in 59% receiving ustekinumab 90 mg, in 67% receiving four weekly 45-mg doses and in 81% of patients receiving four weekly 90-mg doses, whereas only 2% of patients in the placebo group achieved a PASI 75.

Another placebo-controlled double blind randomized crossover study was conducted to evaluate the efficacy of ustekinumab in 146 patients suffering from PsA (A. Gottlieb et al., 2009). Patients were either randomized to receive ustekinumab 90 or 63 mg every week for 4 weeks (weeks 0–3) followed by placebo at weeks 12 and 16 (76 patients, group 1) or placebo (weeks 0–3) and ustekinumab (63 mg) at weeks 12 and 16 (70 patients, group 2). ACR 20 at week 12 (taken as the primary endpoint of the study) was achieved by 42% of patients in group 1 and by 14% in group 2 (P = 0.0002). Significantly more patients in group 1 achieved PASI 75 compared with group 2 in week 12 (52% vs. 5%, P < 0.0001). However, one should note that the dosages of ustekinumab used in the study were higher (90 and 63 mg, respectively) than those recommended for patients of normal weight (45 mg) with psoriasis (Leonardi et al., 2008).

In conclusion, we report the results of the two double-blind, placebo-controlled phase III studies (Phoenix 1 and Phoenix 2) in patients with psoriasis were performed parallel in USA and Europe. Primary outcome in both studies was PASI 75 at week 12 (Leonardi et al., 2008; 211,). 766 patients of Phoenix 1 trial were randomly assigned to receive either ustekinumab 45 mg or 90 mg at weeks 0 and 4 and afterwards every 12 weeks or placebo at weeks 0 and 4 and to cross over at week 12 to ustekinumab (Leonardi et al., 2008; Papp et al., 2008).

Furthermore, patients initially receiving ustekinumab and reaching a PASI 75 at weeks 28 and 40 were re-randomized at week 40 to either continue therapy with ustekinumab or to withdrawal of the study drug until loss of response. Significantly more patients in both ustekinumab groups (45 and 90 mg) received a PASI 75 at week 12 compared with the
placebo group. Patients receiving maintenance therapy up to week 76 significantly better sustained PASI 75 than patients randomized to the drug withdrawal group ($P < 0.0001$).

The design of the Phoenix 2 study closely resembles that of the Phoenix 1 trial (Papp et al., 2008). Of the 1230 patients, 409 patients were randomized to receive ustekinumab 45 mg, 411 to receive ustekinumab 90 mg and 410 to receive placebo at weeks 0 and 4. The efficacy analysis at week 12 revealed the following results for the three groups. The primary endpoint was achieved in 66.7% of the ustekinumab 45-mg group, 75.7% of the ustekinumab 90 mg and 3.7% of the placebo group ($P < 0.0001$ for both ustekinumab 45 and 90 mg vs. placebo).

Quality of life was significantly improved in the patients treated with ustekinumab compared with the placebo groups ($P < 0.0001$) in both Phoenix trials. Patients randomized to maintenance therapy in the Phoenix 1 study were able to sustain improved DLQI scores until the end of the study, whereas in patients withdrawn from the study drug, the DLQI deteriorated again (Leonardi et al., 2008; Papp et al., 2008).

In a randomized active-controlled, parallel three-arm trial (ACCEPT trial), ustekinumab (45 and 90 mg, respectively) was compared versus the anti-TNF-α etanercept (50 mg twice weekly) (C. E. M. Griffiths et al., 2008). The primary endpoint of the study was PASI 75 at week 12. 903 patients were randomized in 3 treatment-arms as follows: 347 patients received etanercept 50 mg subcutaneously twice weekly, 209 patients received ustekinumab 45 mg subcutaneously at weeks 0 and 4, and 347 patients received ustekinumab 90 mg subcutaneously at weeks 0 and 4. PASI 75 at week 12 was achieved by 56.8% of patients in the etanercept group, by 67.5% in the ustekinumab 45-mg group and 73.8% in the ustekinumab 90-mg group. A greater proportion of patients receiving ustekinumab (45 or 90 mg) achieved PASI 75 when compared with the etanercept group ($P = 0.012$ for ustekinumab 45 mg, $P < 0.001$ for ustekinumab 90 mg). Interestingly, PASI 75 values at week 12 in patients receiving etanercept were better than those published in previous studies (Leonardi et al., 2008; Papp et al., 2008).

The table 4 resume the major results obtained using the briakinumab and ustekinumab in psoriasis treatments.

About the major side effects of treatments with ustekinumab; in the phase I studies, no serious adverse events were reported (A. B. Gottlieb et al., 2007; Kaufmann et al., 2004). Adverse events included headaches, abdominal pain and common cold symptoms. Adverse events were comparable in the phase II studies between ustekinumab and placebo groups (79% vs. 72%) (G. G. Krueger et al., 2007). Serious adverse events in patients treated with ustekinumab were infections (2 patients), myocardial infarctions (2 patients), a cerebrovascular accident (1 patient), non-melanoma skin cancer (2 patients) and prostate cancer (1 patient).

In the placebo group, one patient had a basal cell carcinoma and one patient experienced aggravation of his psoriasis requiring hospitalization. In the PsA trial conducted by Gottlieb, the following serious adverse events were reported in the ustekinumab groups: syncope (1 patient), respiratory tract infection (1 patient), haemorrhage (1 patient), stroke (1 patient), congestive heart failure/myocardial infarction/hypertension (1 patient), chest pain (1 patient).
Two serious infections occurred during the placebo-controlled phase of the two large phase III trials: one case of cellulitis and one case of herpes zoster (both in the ustekinumab 90-mg group) (Ding et al., 2008; Ortonne et al., 2007).

During the placebo-controlled phase of the Phoenix 2 study, a squamous cell carcinoma in a patient in the placebo group and a basal cell carcinoma in a patient in the ustekinumab 90-mg group were observed (Ding et al., 2008). Comparing patients on maintenance therapy with patients randomized to the withdrawal group in Phoenix 1 study did not reveal an increased infection rate between the two groups (Ortonne et al., 2007).

<table>
<thead>
<tr>
<th>Therapy</th>
<th>Disease</th>
<th>Trial Type</th>
<th>Treatment (n° of patients)</th>
<th>Major Results</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Briakinumab</td>
<td>Psoriasis</td>
<td>12-week RDBPC</td>
<td>B 200 mg x 1 (30)</td>
<td>PASI 75 at week 12: 63</td>
<td>Kimball et al., 2008</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>B 100 mg eow (3)</td>
<td>PASI 75 at week 12: 93</td>
<td>Arch Dermatol 144: 200–207.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>B 200 mg x 4 (30)</td>
<td>PASI 75 at week 12: 90</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>B 200 mg eow (30)</td>
<td>PASI 75 at week 12: 93</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>B 200 mg weekly (30)</td>
<td>PASI 75 at week 12: 90</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo (30)</td>
<td>PASI 75 at week 12: 1</td>
<td></td>
</tr>
<tr>
<td>Ustekinumab</td>
<td>Psoriasis</td>
<td>RDBPC</td>
<td>U 45 mg (255)</td>
<td>PASI 75 at week 12: 67.1</td>
<td>Leonardi et al., 2008</td>
</tr>
<tr>
<td>PHOENIX 1</td>
<td></td>
<td></td>
<td>U 90 mg (256)</td>
<td>PASI 75 at week 12: 66.4</td>
<td>Lancet 371: 1665 -1674.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo (255)</td>
<td>PASI 75 at week 12: 3.1</td>
<td></td>
</tr>
<tr>
<td>Ustekinumab</td>
<td>Psoriasis</td>
<td>RDBPC</td>
<td>U 45 mg (409)</td>
<td>PASI 75 at week 12: 66.7</td>
<td>Papp et al., 2008</td>
</tr>
<tr>
<td>PHOENIX 2</td>
<td></td>
<td></td>
<td>U 90 mg (411)</td>
<td>PASI 75 at week 12: 75.7</td>
<td>Lancet 371: 1675-1684.</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Placebo (410)</td>
<td>PASI 75 at week 12: 3.7</td>
<td></td>
</tr>
<tr>
<td>Ustekinumab</td>
<td>Psoriasis</td>
<td>RDBPC</td>
<td>U 45 mg (209)</td>
<td>PASI 75 at week 12: 67.5</td>
<td>Griffiths et al., 2010</td>
</tr>
<tr>
<td>ACCEPT</td>
<td></td>
<td></td>
<td>U 90 mg (347)</td>
<td>PASI 75 at week 12: 73.8</td>
<td>N Engl J Med. 362: 118-128</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>E 2 X 50 mg (347)</td>
<td>PASI 75 at week 12: 56.8</td>
<td></td>
</tr>
</tbody>
</table>

B = Briakinumab; E = Etanercept; U = Ustekinumab; RDBPC = Randomized Double-Blind Placebo Controlled Trial

Table 4. Efficacy of anti-IL-12/IL-23 in the psoriasis cure
However, as Th1 and Th17 blockade by ustekinumab might impair cell-mediated immunity, normal KCs host immunity and defence against malignancies, close monitoring in patients on long-term treatment with ustekinumab seems to be appropriate (O’Neill & Kalb, 2009). In the ACCEPT trial, serious adverse events have been observed in 1.2% of patients in the etanercept group, 1.9% in the ustekinumab 45-mg group and 1.2% of patients in the ustekinumab 90 mg group respectively. These included 4 patients in each treatment group: etanercept group: abdominal pain, bacterial meningitis, nephrolithiasis, rotator cuff syndrome; 45-mg ustekinumab group: alcoholic pancreatitis, chest pain/hypertension, psychotic disorder, breast cancer; ustekinumab 90-mg group: urosepsis/renal failure, uveitis, appendicitis and gastroenteritis from food poisoning (C. E. M. Griffiths et al., 2008).

8. Conclusion

Based on a large series of studies, that we discuss in the different paragraphs, current evidence indicates the importance of T cells during psoriasis pathogenesis and demonstrate that T cell expansion precedes the development of typical psoriatic changes; the more reasonable conclusion is that psoriasis is the outcome of an inappropriate T cell-based activation event, together with a defect in KCs, whose combination results in the full psoriatic phenotype.

Once recognized the primary role of T cells in psoriasis pathogenesis, several biological therapies have been developed and proposed to counteract immune T response. These treatments consist in blocking the actions of several T cell cytokines that play a key role in sustain the pathogenesis of early and late events of psoriasis, e.g. anti-IL23 and anti-TNF-α.

So far, considering published data from the clinical trials, the new biological agents have been shown to be efficient treatment options for patients suffering from psoriasis and the major comorbidities disease-associated, primarily PsA.

These new biological agents seem to have proven a good risk/benefit ratio. As psoriasis is considered a life-long disease and no causal therapy for the disease is yet available, long-term studies on safe and efficacious treatments are needed and are of major importance.

Taking into account the possibility that uncommon adverse events or events occurring during long-term exposure to these drugs might emerge in the future (e.g. the development of progressive multifocal leukoencephalopathy in long-term patients treated with efalizumab), vigilant and careful post-marketing surveillance in patients treated with biological agents is strongly recommended.

9. Acknowledgment

We thank Dr. Elena Niccolai for editorial support and Dr. Chiara Della Bella for the artworks. We wish to thank Istituto Superiore di Sanità, and Italian Ministry of University and Research for their support of our studies.

10. References


Chan, J. R., Blumenschein, W., Murphy, E., Diveu, C., Wiekowski, M., Abbondanzo, S., Lucian, L., Geissler, R., Brodie, S., Kimball, A. B., Gorman, D. M., Smith, K., de...


The Role of Immune Response and the Impact of Biological Drugs in Psoriasis Patients


www.intechopen.com


The Role of Immune Response and the Impact of Biological Drugs in Psoriasis Patients


The Role of Immune Response and the Impact of Biological Drugs in Psoriasis Patients


We hope you enjoy and find the information provided in this book useful in your research or practice. We urge that you continue to keep abreast of the new developments in psoriasis and share your knowledge so that we may advance treatment and cures of psoriasis.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: